<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: A major determinant of the progression from <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> to the development of overt type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is a failure to mount an appropriate compensatory beta-cell hyperplastic response to maintain normoglycemia </plain></SENT>
<SENT sid="1" pm="."><plain>We undertook the present study to directly explore the significance of the cell cycle protein cyclin D2 in the expansion of beta-cell mass in two different models of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We created compound knockouts by crossing mice deficient in cyclin D2 (D2KO) with either the insulin receptor substrate 1 knockout (IRS1KO) mice or the insulin receptor liver-specific knockout mice (LIRKO), neither of which develops overt <z:mp ids='MP_0002055'>diabetes</z:mp> on its own because of robust compensatory beta-cell <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>We phenotyped the double knockouts and used RT-qPCR and immunohistochemistry to examine beta-cell mass </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Both compound knockouts, D2KO/LIRKO and D2KO/IRS1KO, exhibited <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> and an absence of compensatory beta-cell <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>However, the diabetic D2KO/LIRKO group rapidly succumbed early compared with a relatively <z:mpath ids='MPATH_458'>normal</z:mpath> lifespan in the <z:chebi fb="105" ids="17234">glucose</z:chebi>-intolerant D2KO/IRS1KO mice </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: This study provides direct genetic evidence that cyclin D2 is essential for the expansion of beta-cell mass in response to a spectrum of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and points to the cell-cycle protein as a potential therapeutic target that can be harnessed for preventing and curing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>